

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.SciCrunch.org) on May 3, 2024

HRI (D-12)

RRID:AB_10843794

Type: Antibody

Proper Citation

(Santa Cruz Biotechnology Cat# sc-365239, RRID:AB_10843794)

Antibody Information

URL: http://antibodyregistry.org/AB_10843794

Proper Citation: (Santa Cruz Biotechnology Cat# sc-365239, RRID:AB_10843794)

Target Antigen: HRI (D-12)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: WB, IP, IF, ELISA; ELISA; Immunoprecipitation; Immunofluorescence; Western Blot

Antibody Name: HRI (D-12)

Description: This monoclonal targets HRI (D-12)

Target Organism: human, mouse, rat

Antibody ID: AB_10843794

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-365239

Ratings and Alerts

No rating or validation information has been found for HRI (D-12).

No alerts have been found for HRI (D-12).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Cordova RA, et al. (2022) GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis. eLife, 11.

Kalkavan H, et al. (2022) Sublethal cytochrome c release generates drug-tolerant persister cells. Cell, 185(18), 3356.

Zarei M, et al. (2019) Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. British journal of pharmacology, 176(13), 2292.